For the first time in 20 years, a physician has become US Secretary of Health and Human Services. On February 10, the Senate voted 52–47 to confirm Tom Price in the post under President Donald Trump. Price is an orthopedic surgeon and Republican congressman from Georgia, who has held a House seat since 2005. He staunchly opposed the Patient Protection and Affordable Care Act and remained a vocal critic of the policy. In his new capacity, Price is expected to lead efforts to dismantle it. Price's appointment was welcomed by the Biosimilars Forum—an industry group that includes Amgen, Boehringer Ingelheim, Merck, Pfizer, Samsung Bioepis, Sandoz and Teva. The group is set to lobby Price to increase access to biosimilars by reversing the current Centers for Medicare & Medicaid Services' reimbursement policy. Previously, in January, the agency finalized guidance to help biosimilar producers understand what data are necessary to demonstrate interchangeability with an originator product. The agency also reiterated naming recommendations first proposed in August 2015, designed to differentiate among non-interchangeable reference products.